A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony diagnoza raka prostaty kwalifikujący się do radioterapii
- •Rak bez przerzutów (stadium M0)
- •Wiek od 18 do poniżej 70 lat
- •Dobry stan ogólny pozwalający na uczestnictwo w badaniu
- •Prawidłowa funkcja nerek (wynik testu kreatyniny większy niż 30)
- •Prawidłowe wyniki badań krwi (hemoglobina minimum 9,0, płytki krwi minimum 100 000)
- •Ciśnienie skurczowe powyżej 130 mmHg
- •Znajomość języka angielskiego
✗ Disqualifies
- •Poprzednia radioterapia miednicy
- •Przyjmowanie leku lisinopril lub podobnych leków w ciągu ostatnich 2 miesięcy
- •Alergia na lisinopril
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- July 23, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Wilmot Cancer Institute
Rochester, United States
Trial contact
Therese Smudzin
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.